Survival outcome of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab (ET plus T plus P) vs. de-escalated chemotherapy (CT) plus T plus P in hormone receptor positive (HR+)/HER2+early breast cancer (EBC): WSG-TP-II trial

被引：0
|
作者：
Gluz, O. [1 ]
Nitz, U. A. [2 ]
Christgen, M. [3 ]
Kummel, S. [4 ]
Holtschmidt, J. [5 ]
Schumacher, J. [6 ]
Hartkopf, A. D. [7 ]
Luedtke-Heckenkamp, K. [8 ]
Just, M. [9 ]
von Schumann, R. [10 ]
Polata, S. [11 ]
Schinkoethe, T. [12 ]
Graeser-Mayer, M. K. [13 ]
Kates, R. E. [14 ]
Wuerstlein, R. [15 ]
Kreipe, H. [3 ]
Harbeck, N. [16 ]
机构：
[1] Evangeliches Krankenhaus Bethesda Klin, Breast Ctr, Monchengladbach, Germany
[2] West German Study Grp, Senol, Monchengladbach, Germany
[3] MHH, Pathol, Hannover, Germany
[4] Kliniken Essen Mitte Evang Huyssens Stiftung, Breast Unit, Essen, Germany
[5] St Elisabeth Clin Hohenlind, Breast Ctr, Cologne, Germany
[6] Palleos GmbH, Stat, Wiesbaden, Germany
[7] Univ Hosp Tubingen, Ctr Womens Hlth, Tubingen, Germany
[8] Niels Stensen Kliniken GmbH, Franziskus Hosp Harderberg, Oncol Dept, Georgsmarienhutte, Germany
[9] Onkol Schwerpunkt Praxis, Oncol, Greifswald, Germany
[10] Johanniter Bethesda Moenchengladbach, Breast Ctr Niederrhein, Monchengladbach, Germany
[11] Oncol Ctr Spandau, Oncol, Berlin, Germany
[12] LMU Klinikum Univ Munchen, Breast Ctr, Munich, Germany
[13] Westdeutsch Studiengrp GmbH, Senol, Monchengladbach, Germany
[14] Westdeutsch Studiengrp GmbH, Breast Ctr Dept, Monchengladbach, Germany
[15] LMU Klinikum Univ Munchen, Breast Ctr Dept, Munich, Germany
[16] LMU Univ Hosp, Dept Obstet & Gynecol, Breast Ctr, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA17
引用
收藏
页码：1210 / 1210
页数：1
相关论文
共 50 条
  • [1] De-escalated chemotherapy versus endocrine therapy plus pertuzumab plus trastuzumab for HR+/HER2+early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.
    Gluz, Oleg
    Nitz, Ulrike
    Christgen, Matthias
    Kuemmel, Sherko
    Holtschmidt, Johannes
    Priel, Jan
    Hartkopf, Andreas
    Potenberg, Jochem
    Luedtke-Heckenkamp, Kerstin
    Just, Marianne
    Wuelfing, Pia
    Von Schumann, Raquel
    Graeser, Monika
    Wuerstlein, Rachel
    Kates, Ronald E.
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer The Neoadjuvant WSG-TP-II Randomized Clinical Trial
    Gluz, Oleg
    Nitz, Ulrike A.
    Christgen, Matthias
    Kuemmel, Sherko
    Holtschmidt, Johannes
    Schumacher, Johannes
    Hartkopf, Andreas
    Potenberg, Jochem
    Lueedtke-Heckenkamp, Kerstin
    Just, Marianne
    Schem, Christian
    von Schumann, Raquel
    Kolberg-Liedtke, Cornelia
    Eulenburg, Christine Zu
    Schinkoethe, Timo
    Graeser, Monika
    Wuerstlein, Rachel
    Kates, Ronald E.
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    JAMA ONCOLOGY, 2023, 9 (07) : 946 - 954
  • [3] De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab plus ET in early HR+/HER2+breast cancer (BC): ADAPT-TP survival results
    Harbeck, N.
    Nitz, U.
    Christgen, M.
    Kuemmel, S.
    Braun, M.
    Schumacher, C.
    Potenberg, J.
    Tio, J.
    Aktas, B.
    Malter, W.
    Forstbauer, H.
    von Schumann, R.
    Just, M.
    Jozwiak, K.
    Hauptmann, M.
    Kates, R.
    Graeser, M.
    Wuerstlein, R.
    Kreipe, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1146 - S1146
  • [4] APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).
    Von Minckwitz, Gunter
    Procter, Marion Jennifer
    De Azambuja, Evandro
    Zardavas, Dimitrios
    Knott, Adam
    Viale, Giuseppe
    Suter, Thomas M.
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Benyunes, Mark
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart-Gebhart, Martine J.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [5] APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)
    Von Minckwitz, Gunter
    Procter, Marion Jennifer
    De Azambuja, Evandro
    Zardavas, Dimitrios
    Knott, Adam
    Viale, Giuseppe
    Suter, Thomas M.
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Benyunes, Mark
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gleber, Richard D.
    Piccart-Gebhart, Martine J.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] De-escalated neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel weekly in HR-/HER2+early breast cancer: ADAPT-HR-/HER2+biomarker and survival results.
    Harbeck, Nadia
    Gluz, Oleg
    Christgen, Matthias
    Kuemmel, Sherko
    Grischke, Eva-Maria
    Braun, Michael
    Potenberg, Jochem
    Krauss, Katja
    Schumacher, Claudia
    Forstbauer, Helmut
    Reimer, Toralf
    Stefek, Andrea
    Fischer, Hans Holger
    Pelz, Enrico
    Graeser, Monika
    zu Eulenburg, Christine
    Kates, Ronald E.
    Wuerstlein, Rachel
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR plus ) breast cancer: A phase II feasibility study
    Mayer, Erica L.
    Gropper, Adrienne Brana
    Tung, Nadine M.
    Higgins, Michaela Jane
    Traina, Tiffany A.
    Barry, William Thomas
    Winer, Eric P.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K] pertuzumab (P) vs docetaxel plus carboplatin plus trastuzumab plus P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE)
    Hurvitz, Sara A.
    Martin, Miguel
    Symmans, William Fraser
    Jung, Kyung Hae
    Huang, Chiun-Sheng
    Thompson, Alastair Mark
    Harbeck, Nadia
    Valero, Vicente
    Stroyakovskiy, Daniil
    Wildiers, Hans
    Afenjar, Karen
    Fresco, Rodrigo
    Helms, Hans -Joachim
    Xu, Jin
    Lin, Yvonne Gail
    Sparano, Joseph A.
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
    Harbeck, N.
    Nitz, U.
    Christgen, M.
    Kuemmel, S.
    Braun, M.
    Biehl, C. M.
    Schumacher, C.
    Malter, W.
    Aktas, B.
    Forstbauer, H.
    Tio, J.
    Grischke, E-M.
    Kolberg-Liedtke, C.
    de Haas, S.
    Deurloo, R. J.
    Kates, R. E.
    Zu, C. Eulenburg
    Wuerstlein, R.
    Kreipe, H.
    Gluz, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S1285 - S1285
  • [10] VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab plus pertuzumab plus trastuzumab plus chemotherapy (neoadj A plus PH plus CT) in high-risk, HER2-positive early breast cancer (EBC)
    Huober, J.
    Barrios, C. H.
    Niikura, N.
    Jarzab, M.
    Chang, Y-C.
    Huggins-Puhalla, S. L.
    Graupner, V.
    Eiger, D.
    Henschel, V.
    Gochitashvili, N.
    Lambertini, C.
    Restuccia, E.
    Zhang, H.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 1061 - 1062
12345